Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)

41,800 -0,300 (-0,71%) Ab 03:20PM HKT. Markt geöffnet.

Shanghai Haohai Biological Technology Co., Ltd.

WenGuang Plaza
23rd Floor No. 1386, Hongqiao Road Changning District
Shanghai
China
86 21 5229 3555
https://www.3healthcare.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.158

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Yongtai Hou	Executive Chairman	1,79M	N/A	1962
Dr. Jianying Wu	GM & Executive Director	1,86M	N/A	1964
Mr. Minjie Tang	CFO & Executive Director	1,44M	N/A	1975
Ms. Yiyi Chen	Executive Director	1,23M	N/A	1982
Mr. Ming King Chiu FCIS, FCS	Joint Company Secretary	N/A	N/A	1977
Ms. Min Tian	Joint Company Secretary	N/A	N/A	1989
Ms. Caixia Ren	Deputy General Manager	N/A	N/A	1958

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in HKD.

Beschreibung

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, soft contact lens, medical sodium hyaluronate gels, injectors, scalpels, suture needles, and other products; orthopedics products, such as sodium hyaluronate injection and medical chitosan products; and anti-adhesion products, including medical sodium hyaluronate gel, and medical chitosan and collagen sponge products. The company also provides medical aesthetics products comprising Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; recombinant human epidermal growth factor products; and radio frequency devices and laser equipment. In addition, it is involved in the research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; sale of professional life and home cosmetology machines; and manufacture and sale of biological reagents, biologicals and biological materials, and other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Corporate Governance

Shanghai Haohai Biological Technology Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.